Business

Compass Therapeutics to Present at the 38th Annual JP Morgan Healthcare Conference


Compass Therapeutics , a clinical-stage biotechnology company targeting the human immune synapse with a new generation of monoclonal and multispecific antibody therapeutics, today announced that Thomas Schuetz, M.D., Ph.D., co-founder and chief executive officer, will present a company overview at the 38 th Annual J.P. Morgan Healthcare Conference in San Francisco, CA, on Monday, January 13, 2020.


In his presentation, Dr. Schuetz will describe the clinical development strategy and share early clinical data of the company’s lead candidate, CTX-471, a fully human agonistic antibody of CD137 now in a Phase 1 study in selected patients with advanced solid tumors.


Additionally, Dr. Schuetz will provide an update on CTX-8371, a novel PD-1/PD-L1 bispecific which has shown significantly increased activity compared to approved PD-1/PD-L1 therapies in preclinical testing.


Compass is leveraging its proprietary StitchMabs TM and common light-chain based multispecific platforms to empirically identify multispecifics and combinations of antibody therapeutics that synergistically modulate key nodes in the immune system.


The company’s lead product candidate, CTX-471, is a fully human agonistic antibody of CD137, which is in a Phase 1 study in patients with inadequate responses to PD-1/PD-L1 checkpoint inhibitors.


The company’s offices and labs are based in Kendall Square in Cambridge, Mass.






Powered by Blogger.